- Home
- ANL vs ALEC Comparison
ANL vs ALEC Comparison
Compare ANL & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | ALEC |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.4M | 262.7M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANL | ALEC |
|---|---|---|
| Price | $7.10 | $2.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $16.00 | $4.83 |
| AVG Volume (30 Days) | 196.2K | ★ 747.9K |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $0.87 |
| 52 Week High | $12.09 | $3.40 |
Technical Indicators
Market Signals| Indicator | ANL | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 46.09 |
| Support Level | $1.36 | $1.82 |
| Resistance Level | $9.98 | $2.55 |
| Average True Range (ATR) | 0.89 | 0.15 |
| MACD | -0.33 | -0.03 |
| Stochastic Oscillator | 13.03 | 21.32 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.